• 

  Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. 

  Khan, AA; Paget, JT; McLaughlin, M; Kyula, JN; Wilkinson, MJ; Pencavel, T; Mansfield, D; Roulstone, V; Seth, R; Halle, M; Somaiah, N; Boult, JKR; Robinson, SP; Pandha, HS; Vile, RG; Melcher, AA; Harris, PA; Harrington, KJ (2018-01-24)

  Improvements in cancer survival mean that long-term toxicities, which contribute to the morbidity of cancer survivorship, are being increasingly recognized. Late adverse effects (LAEs) in normal tissues after radiotherapy ...
• 

  Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy. 

  Dean, J; Wong, K; Gay, H; Welsh, L; Jones, A-B; Schick, U; Oh, JH; Apte, A; Newbold, K; Bhide, S; Harrington, K; Deasy, J; Nutting, C; Gulliford, S (2018-01)

  Severe acute dysphagia commonly results from head and neck radiotherapy (RT). A model enabling prediction of severity of acute dysphagia for individual patients could guide clinical decision-making. Statistical associations ...
• 

  Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. 

  Samson, A; Scott, KJ; Taggart, D; West, EJ; Wilson, E; Nuovo, GJ; Thomson, S; Corns, R; Mathew, RK; Fuller, MJ; Kottke, TJ; Thompson, JM; Ilett, EJ; Cockle, JV; van Hille, P; Sivakumar, G; Polson, ES; Turnbull, SJ; Appleton, ES; Migneco, G; Rose, AS; Coffey, MC; Beirne, DA; Collinson, FJ; Ralph, C; Alan Anthoney, D; Twelves, CJ; Furness, AJ; Quezada, SA; Wurdak, H; Errington-Mais, F; Pandha, H; Harrington, KJ; Selby, PJ; Vile, RG; Griffin, SD; Stead, LF; Short, SC; Melcher, AA (2018-01-03)

  Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined ...
• 

  HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. 

  Martins, CD; Da Pieve, C; Burley, TA; Smith, R; Ciobota, DM; Allott, L; Harrington, KJ; Oyen, WJG; Smith, G; Kramer-Marek, G (2018-02-06)

  Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ...
• 

  3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. 

  Iveson, TJ; Kerr, RS; Saunders, MP; Cassidy, J; Hollander, NH; Tabernero, J; Haydon, A; Glimelius, B; Harkin, A; Allan, K; McQueen, J; Scudder, C; Boyd, KA; Briggs, A; Waterston, A; Medley, L; Wilson, C; Ellis, R; Essapen, S; Dhadda, AS; Harrison, M; Falk, S; Raouf, S; Rees, C; Olesen, RK; Propper, D; Bridgewater, J; Azzabi, A; Farrugia, D; Webb, A; Cunningham, D; Hickish, T; Weaver, A; Gollins, S; Wasan, HS; Paul, J (2018-04)

  BACKGROUND: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior ...

View more